. . . . . "Ben\u0161ov\u00E1, Lucie" . . "3"^^ . . "227509" . . . "RIV/26475821:_____/11:#0000125" . "KRAS mutations can be found in 15 to 25% of lung cancers, frequently in adenocarcinomas and their presence is associated with smoking. The role of KRAS mutations in biological targeted therapy by EGFR inhibitors is ambiguous. While some reports clearly assigned mutated KRAS as negative prognostic factor and negative predictor, others did not confirm such notion. In our work we aimed to elucidate the role of specific type of KRAS mutation in outcome of patients with advanced NSCLC threated with EGFR-TKI therapy." . "Min\u00E1rik, Marek" . . . "RIV/26475821:_____/11:#0000125!RIV12-MZ0-26475821" . "KRAS mutations can be found in 15 to 25% of lung cancers, frequently in adenocarcinomas and their presence is associated with smoking. The role of KRAS mutations in biological targeted therapy by EGFR inhibitors is ambiguous. While some reports clearly assigned mutated KRAS as negative prognostic factor and negative predictor, others did not confirm such notion. In our work we aimed to elucidate the role of specific type of KRAS mutation in outcome of patients with advanced NSCLC threated with EGFR-TKI therapy."@en . . "The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors." . . "P(NS9718)" . "The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors."@en . "[959EF12D6FAF]" . "Bel\u0161\u00E1nov\u00E1, Barbora" . "5"^^ . . "The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors." . . "The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors."@en . "KRAS mutation; treatment; EGFR inhibitors"@en . . . .